Haematology, Launceston General Hospital, Launceston, Tasmania, Australia
BMJ Case Rep. 2021 Oct 28;14(10):e244656. doi: 10.1136/bcr-2021-244656.
A 25-year-old woman with a history of immune thrombocytopaenia (ITP) in childhood was referred to haematology clinic for review with a platelet count of 50 μ/L at 9 weeks gestation, gravida 2, para 0. She developed progressive severe thrombocytopaenia as the pregnancy progressed, with associated bleeding complications. The thrombocytopaenia was refractory to standard therapies. This led to a need for a planned delivery, which was performed via caesarean section under general anaesthetic with platelet transfusion support, Intravenous Immune Globulin (IVIG), high-dose corticosteroid and the thrombopoietin (TPO) mimetic romiplostim. Both the mother and the neonate survived; however, the neonate required treatment for severe prolonged neonatal thrombocytopaenia. The patient subsequently re-presented 15 months later with recurrent ITP complicating another pregnancy, refractory to rituximab but responsive to romiplostim. She had a successful elective caesarean section under epidural anaesthesia, but the neonate once again suffered severe thrombocytopaenia, which was responsive to IVIG.
一位 25 岁女性,儿时患有免疫性血小板减少症(ITP),怀孕 9 周时因血小板计数为 50 μ/L 被转诊至血液科门诊,孕 2 产 0。随着妊娠的进展,她的血小板减少症逐渐加重并出现严重出血并发症。血小板减少症对标准治疗无效,因此需要计划分娩。在全身麻醉下进行剖宫产,并给予血小板输注支持、静脉注射免疫球蛋白(IVIG)、大剂量皮质类固醇和血小板生成素(TPO)模拟物罗米司亭。母婴均存活,但新生儿因严重持续新生儿血小板减少症需要治疗。15 个月后,该患者再次因妊娠并发复发性 ITP 就诊,对利妥昔单抗无效,但对罗米司亭有反应。她在硬膜外麻醉下成功进行了选择性剖宫产,但新生儿再次出现严重血小板减少症,对 IVIG 有反应。